Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms

References

• Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680–692.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–3184.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–1881.
   PubMed Web of Science ®Google Scholar
• Geyer H, Mesa RA. Approach to MPN symptom assessment. Curr Hematol Malig Rep. 2017;12(5):381–388.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Myeloproliferative Neoplasms, Version 1. 2020. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–408.
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–4103.
   PubMed Web of Science ®Google Scholar
• Nelson EC, Eftimovska E, Lind C, et al. Patient reported outcome measures in practice. BMJ. 2015;350:g7818.
   PubMed Web of Science ®Google Scholar
• Johansson P, Mesa R, Scherber R, et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012;53(3):441–444.
   PubMed Web of Science ®Google Scholar
• Mesa R, Boccia RV, Grunwald MR, et al. Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18(9):590–596.
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96(10):1653–1665.
   PubMed Web of Science ®Google Scholar
• Langlais BT, Geyer H, Scherber R, et al. Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma. 2019;60(2):402–408.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.
   PubMed Web of Science ®Google Scholar
• Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015;90(10):864–870.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Kosiorek H, Dueck AC, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica. 2017; 102(1):85–93.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Andreasson B, Kosiorek HE, et al. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: an analysis by the MPN QOL International Study Group. Cancer. 2016;122(12):1888–1896.
   PubMed Web of Science ®Google Scholar
• Grunwald MR, Burke JM, Kuter DJ, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2019;19(9):579–584 e1.
   PubMed Web of Science ®Google Scholar
• Scotch AH, Kosiorek H, Scherber R, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs. Leuk Res. 2017;63:34–40.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–3810.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017;123(3):449–458.
   PubMed Web of Science ®Google Scholar
• Brochmann N, Flachs EM, Christensen AI, et al. Health-related quality of life in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Cancers (Basel). 2020;12(12):3565.
   PubMed Web of Science ®Google Scholar
• Mehta J, Wang H, Fryzek JP, et al. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma. 2014;55(10):2368–2374.
   PubMed Web of Science ®Google Scholar
• Yassin MA, Taher A, Mathews V, et al. MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med. 2020;9(13):4512–4526.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Thein HH, Anyiwe K, Jembere N, et al. Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: a population-based cohort study. PLoS One. 2017;12(10):e0186350.
   PubMed Web of Science ®Google Scholar
• Patel MI, Schupp CW, Gomez SL, et al. How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox. J Clin Oncol. 2013;31(28):3572–3578.
   PubMed Web of Science ®Google Scholar
• Keegan TH, Grogan RH, Parsons HM, et al. Sociodemographic disparities in differentiated thyroid cancer survival among adolescents and young adults in California. Thyroid. 2015;25(6):635–648.
   PubMed Web of Science ®Google Scholar
• Everist MM, Howard LE, Aronson WJ, et al. Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: results from the SEARCH database. Urol Oncol. 2019;37(4):289 e11–289 e17.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Pascutto C, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–1069.
   PubMed Web of Science ®Google Scholar
• ElNahass YH, Mahmoud HK, Mattar MM, et al. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients. Leuk Lymphoma. 2018;59(4):844–854.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa Ra Fau - Gotlib J, Gotlib J, Fau - Levy RS, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Jin J, Du X, Zhou DB, et al. Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202. Zhonghua Xue Ye Xue Za Zhi. 2016;37(10):858–863.
   PubMedGoogle Scholar